How to Choose Between Best Growth Hormone Peptides Based on Goals, Access, and Medical History

The choice rarely comes down to which compound. For a diagnosed pituitary disorder, treatment is growth hormone replacement under endocrinology care, not a peptide menu. For muscle, fat loss, recovery, or aging in an otherwise healthy adult, no compound in this category has established benefit, so the real decision is whether to start anything.

It also helps to see this category as one storefront in a larger direct-to-consumer market. The telehealth companies selling growth hormone peptides frequently sell unrelated prescriptions beside them, so the same intake flow that offers a peptide may also offer weight loss or men’s health drugs. Ro, Hims and Hers, and LillyDirect each run several product lines, and HealthRX lists ED treatment among its categories. The breadth of a menu is a marketing fact, not a clinical one, and it should not stand in for the evaluation this decision needs.

Begin with the diagnosis question

Adult growth hormone deficiency is a defined clinical condition, usually arising from pituitary or hypothalamic disease, surgery, radiation, or traumatic brain injury. It is diagnosed with stimulation testing interpreted against clinical context, and the Endocrine Society guideline sets out who should be tested and how. Where deficiency is confirmed, the treatment with an evidence base is recombinant growth hormone, prescribed and titrated by a specialist.

Low IGF-I on a single screening panel is not the same as a diagnosis, and neither is a symptom list built from fatigue, weight change, and poor sleep. Those overlap with sleep apnea, depression, thyroid disease, anemia, and ordinary aging. A provider who moves from one questionnaire to a prescription has skipped the step that determines whether any of this applies.

Match the goal to what has been shown

Stated goal	What the evidence supports	Reasonable next step
Confirmed adult growth hormone deficiency	Growth hormone replacement, guideline-directed	Endocrinology referral and stimulation testing
Excess abdominal fat with HIV-associated lipodystrophy	Tesamorelin, the one approved product in the category	Discuss with the treating HIV clinician
Muscle growth or strength	Nothing. Growth hormone raised lean mass without improving strength	Training and protein intake, which do have evidence
Fat loss	Modest fat mass change in growth hormone trials, with adverse events	Established weight management pathways
Antiaging or general vitality	Reviewed and not recommended for this purpose	Screening for treatable causes of the symptoms
Injury recovery or sleep quality	Anecdote and small physiology studies, no outcome trials	Address the specific problem directly

The pattern is consistent. Where an approval exists, it is narrow. Where the marketing is broad, the evidence is absent.

Medical history that changes the answer

Several histories shift this from an open question to a clear no, or at minimum require specialist input rather than a telehealth intake form.

Impaired glucose tolerance, insulin resistance, or type 2 diabetes matter because this whole class pushes glucose in the wrong direction. The randomized MK-677 trial in healthy older adults recorded rising fasting glucose and falling insulin sensitivity, and a review of secretagogues named blood glucose as the recurring concern.

Heart failure is another. FDA has flagged ibutamoren for significant safety risks on the basis of a randomized trial in patients recovering from hip fracture that was terminated early over a potential congestive heart failure signal.

Active or recent malignancy warrants specialist input, since the growth hormone and IGF-I axis is under long-standing scrutiny in that context and long-term cancer outcome data for secretagogues does not exist. Pituitary disease, pregnancy, and treatment in anyone under eighteen all belong with a specialist rather than a general wellness service. Existing joint problems and carpal tunnel symptoms are relevant too, because those were among the more common adverse events in growth hormone trials.

Access shapes what you are actually buying

Three routes exist, and they are not equivalent. An approved product dispensed for its labeled indication is the only route with a manufacturer, a reviewed label, and a supply chain FDA inspects. A compounded preparation from a licensed pharmacy, on a valid prescription, is legitimate practice but is not FDA-approved and is not reviewed for safety, effectiveness, or quality. Vials bought online with a research-only disclaimer sit outside medical practice entirely, and nothing about their contents has been verified.

Within the compounded route, providers differ more than products do. Some run laboratory work and a real evaluation before prescribing; others send a questionnaire. Practices including Defy Medical and Hone Health run prescriber-led hormone programs, and cash-pay platforms are increasingly explicit about what a program includes. Before starting, it is worth asking the provider behind it what evaluation happens first, who prepares the medication, and what triggers a decision to stop. Those answers separate a clinical service from an order form more reliably than the price does.

If you compete in tested sport, the decision is made

Growth hormone, its releasing factors, and its secretagogues are prohibited at all times under the World Anti-Doping Code, in and out of competition. A valid prescription does not change that, and neither does compounded status. Athletes in collegiate, national, or international testing pools who take any compound in this category are exposed to a sanction, and a therapeutic use exemption for the wellness indications people usually want is not realistic.

Questions that reveal what kind of service this is

Ask what condition is being treated and how it was established. Ask what the measurable target is and when it will be reassessed. Ask which laboratory values will be tracked and at what intervals. Ask what would cause the prescriber to stop, rather than switch. Ask what happens to the prescription if a value moves the wrong way.

A service that can answer those in specifics is doing clinical work. One that redirects to a compound comparison is selling a product.

Frequently asked questions

How is adult growth hormone deficiency actually diagnosed?

Through stimulation testing interpreted alongside clinical history, usually in the context of known pituitary or hypothalamic disease, surgery, radiation, or head injury. Guideline recommendations set out who warrants testing. A single low IGF-I value on a wellness panel does not establish the diagnosis.

Should someone healthy pick sermorelin or ipamorelin?

Neither has demonstrated benefit for the goals healthy adults typically bring. Sermorelin has no current FDA-approved label and is supplied compounded; ipamorelin has no approval and appears in an FDA category flagging significant safety risks for compounding. The comparison assumes a benefit that has not been shown.

Does a family history of diabetes matter here?

It is worth raising. The class reduces insulin sensitivity, and randomized data on both growth hormone and the oral secretagogue MK-677 recorded rising glucose measures. Anyone already at metabolic risk carries that concern into any decision about starting.

Is tesamorelin an option for general abdominal fat?

No. Its approval covers reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, and the label states plainly that it is not indicated for weight loss management. Use outside that indication has neither approval nor supporting trial evidence.

What if a provider says lab work is unnecessary?

Treat it as information about the provider. Baseline and follow-up testing are the only way to know whether anything is changing and whether glucose is drifting. A program with no measurements cannot tell success from failure, or safety from harm.